Drug resistance mutations and viral load in human immunodeficiency virus type 2 and dual HIV-1/HIV-2 infected patients in Ghana

Christopher Z. Abana, MPHi,a, Kwamena W.C. Sagoe, PhDb, Evelyn Y. Bonney, PhDb, Edward K. Maina, PhDc,d, Ishmael D. Aziati, BScde,e, Esinam Agbosu, BScf,g, Gifty Mawuli, BScg, Linda M. Styer, PhDd, Koichi Ishikawa, Phdf, James A.M. Brandful, PhDa, William K. Ampofo, Phdf

Abstract
Antiretroviral therapy (ART) and drug resistance studies worldwide have focused almost exclusively on human immunodeficiency virus type 1 (HIV-1). As a result, there is limited information on ART and drug resistance in HIV-2 patients. In Ghana, the HIV epidemic is characterized by the domination of HIV-1, with cocirculating HIV-2. We, therefore, sought to determine viral load and drug resistance mutations in HIV-2 patients to inform the clinical management of such individuals in Ghana.

We used purposive sampling to collect blood from 16 consented patients, confirmed as HIV-2 or HIV-1/2 dual infections by serology. A 2-step real-time RT-PCR assay was used to determine plasma HIV-2 RNA viral loads. For drug resistance testing, nucleic acids were extracted from plasma and peripheral blood mononuclear cells. The reverse transcriptase and protease genes of HIV-2 were amplified, sequenced and analyzed for drug resistance mutations and HIV-2 group.

HIV-2 viral load was detected in 9 of 16 patients. Six of these had quantifiable viral loads (range: 2.62–5.45 log IU/mL) while 3 had viral loads below the limit of quantification. Sequences were generated from 7 out of 16 samples. Five of these were classified as HIV-2 group B and 2 as HIV-2 group A. HIV-2 drug resistance mutations (M184V, K65R, Y115F) were identified in 1 patient. This study is the first to report HIV-2 viral load and drug resistance mutations in HIV-2 strains from Ghana. The results indicate the need for continuous monitoring of drug resistance among HIV-2-infected patients to improve their clinical management.

Abbreviations: 3TC = lamivudine, ABC = abacavir, ABI = applied biosystems, AIDS = acquired immunodeficiency syndrome, ART = antiretroviral therapy, AZT = zidovudine, Bp = base pair, CD4 = cluster of differentiation 4, CQN = certifed protocol number, DNA = deoxyribonucleic acid, dNTPs = Deoxyribonucleotide triphosphate, EFV = efavirenz, HIV = human immunodeficiency virus, HIV-2 = human immunodeficiency virus type 2, IRB = Institutional Review Board, IU = international unit, LLOQ = lower limit of quantification, NMIMR = Noguchi Memorial Institute for Medical Research, NNRTIs = non-nucleoside reverse transcriptase inhibitors, NRTIs = nucleoside reverse transcriptase inhibitors, PBMC = peripheral blood mononuclear cells, PCR = polymerase chain reaction, PI = protease inhibitor, PR = protease, RNA = ribonucleic acid, RT = reverse transcriptase, TDF = tenofovir, UNAIDS = Joint United Nations Programme on HIV/AIDS.

Keywords: antiretroviral therapy, drug resistance, HIV-2, mutation, viral load
1. Introduction

It is estimated that 36.7 million people worldwide are living with the human immunodeficiency virus (HIV). Sub-Saharan Africa is most affected, with 25.8 million people living with HIV in 2015. HIV type 1 (HIV-1) and type 2 (HIV-2) infections have been described with HIV-1 responsible for over 90% of the global acquired immunodeficiency syndrome (AIDS) pandemic. Two million people are known to be infected with HIV-2, most of whom live in West Africa. HIV-2 infection has spread to other countries in Europe, Asia, and North America with a high prevalence (5.4%) reported in Portugal. HIV-1 and HIV-2 have similar routes of transmission, however, HIV-2 is associated with disease progression.

The HIV epidemic in Ghana is characterized by cocirculation of both viruses with HIV-1 being predominant. In view of this, the national antiretroviral therapy (ART) guidelines for the management of HIV/AIDS patients make provisions specifically for persons with HIV-2 and HIV-1/2 dual infections. For such individuals, the guidelines recommend a protease inhibitor (PI)-based regimen instead of those based on non-nucleoside reverse transcriptase inhibitor (NNRTI). In 2017, the estimated adult national HIV prevalence in Ghana was 1.67% with 99% HIV-1, 0.2% HIV-2, and 0.8% HIV-1/2 dual infections.

The emergence of drug-resistant strains during treatment is a major obstacle to the success of any ART program. Both HIV-1 and HIV-2 are known to develop resistance against antiretroviral drugs. The development of drug resistance in HIV-2 infections globally has been examined in several studies, however, information is scarce on HIV-2 drug resistance.

Previous studies in Ghana have documented drug resistance mutations in treatment-naive or experienced HIV-1 patients. However, there is little drug resistance data on HIV-2 infected patients in Ghana, probably due to the lack of commercially available HIV-2 viral load assays and optimized HIV-2 genotyping protocols. This study therefore aimed to investigate viral loads and drug resistance mutations in HIV-2 and dual HIV-1/HIV-2-infected patients from Ghana.

2. Methods

2.1. Study design and population

This was a cross-sectional study that recruited patients from ART care centers at the Eastern Regional Hospital, Koforidua and the Korle-Bu Teaching Hospital, Accra from November 2014 to June 2015. The participants were limited to Ghanaian men and women aged 18 years and older. There were 2 cohorts in this study; an ART-naive group and an ART-experienced group. Patients eligible for the study included patients who were seropositive for HIV-2 or dual HIV-1/2. To be able to identify such patients, we searched for patients who were diagnosed as HIV-2 or dual HIV-1/2 from the hospital folders. Purposive sampling was therefore used to collect blood from 27 consenting patients who were seropositive for HIV-2 or dual HIV-1/2 using First Response HIV-1/2-0 card test (Premier Medical Corporation Ltd, India) performed at the hospitals. The status of these patients was confirmed as HIV-2 or dual HIV-1/2 using the innogenetics line immuno assay HIV-II score assay (Fujirebio Europe N. V, Belgium). After confirmatory testing, 16 patients; 10 ART-naive and 6 ART-experienced, who agreed to take part in the study were enrolled after written informed consent was sought. Sample size was determined based on the national prevalence of HIV-2 (0.8%) in Ghana for 2014 using a f value of 1.96 at 95% confidence level and 0.05 confidence interval. Clinical histories were retrieved from hospital folders of study patients. The study was conducted in accordance with procedures approved by the Institutional Review Board of the Noguchi Memorial Institute for Medical Research (NMIMR-IRB CPN 063/14-15) and the Ethical and Protocol Review Committee of the University of Ghana Medical School (MS-Et/M.4-P.4.3/2014-2015).

2.2. Whole blood processing into plasma and peripheral blood mononuclear cells

Blood was processed into plasma and peripheral blood mononuclear cells (PBMC) using a sucrose-based gradient protocol with Histopaque 1077 (Sigma Aldrich Company; Darmstadt, Germany). Plasma was stored at −80°C while PBMCs were stored in freezing medium, consisting of 1% dimethyl sulfoxide (DMSO) (Sigma Aldrich, Germany) in fetal bovine serum (Sigma Aldrich), at −80°C until use.

2.3. Nucleic acid extraction and purification

Ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) were extracted from plasma and PBMCs, respectively using the QIAamp viral RNA mini kit and the DNAeasy Blood and Tissue kit (Qiagen, Germany) according to the manufacturer’s instructions.

2.4. HIV-2 viral load and genotyping

HIV-2 viral load was performed on 0.2 ml of plasma following a published protocol. Viral load testing was completed at the Wadsworth Center, New York State Department of Health according to the approved IRB protocol (#17-039). The HIV-2 viral load assay had a lower limit of detection of 32 international units (IU)/ml (1.50 log IU/ml) and a lower limit of quantification (LLOQ) of 2.25 IU/ml (2.35 log IU/ml). For genotyping, reverse transcriptase (RT) and protease (PR) genes of HIV-2 were amplified separately using specific primers. A nested polymerase chain reaction (PCR) for the RT gene from PBMC portions was carried out to amplify a genomic region of 1050 base pairs (bp) encoding the RT gene (Table 1). The reactions were carried out in a total volume of 25 μl containing 5 μl of DNA template, 12.5 μl of Supermix (Life Technologies, Invitrogen; Austin, TX) and 0.5 μl of 20 μM of primers (Table 1). The first round PCR conditions were: 94°C for 2 minutes, 40 cycles of 94°C for 30 seconds, 55°C for 1 minute and 72°C for 1 minute 30 seconds, and then an elongation step at 72°C for 7 minutes. A nested PCR was carried out using 5 μl of the first-round PCR product under the following cycle conditions: 94°C for 2 minutes, 40 cycles of 94°C for 30 seconds, 56°C for 1 minute and 72°C for 1 minute, and an extension at 72°C for 5 minutes. The entire coding region for the PR gene (297 bp) was amplified by nested PCR using primers (Table 1). The cycling conditions for PR gene PCRs were the same as that for RT gene.

The RT and PR genes in plasma were amplified by nested PCR using QIAGEN OneStep RT-PCR Kit (Qiagen, Germany) for the first round in a total reaction volume of 25 μl containing 5 μl of RNA, 5 μl of 5× buffer, 0.75 μl of 20 μM of primers, 1 μl of...
Details of primers used to amplify HIV-2 sub-genomic fragments previously published.

| Name     | Position in HIV-2 ROD sequence | Nucleotide sequence: from 5’ to 3’ end | Purpose/target region          |
|----------|-------------------------------|----------------------------------------|--------------------------------|
| RT2      | 3503–3526                     | GAGGCTATTAAAGAGATCTGCAAAATAGTGG        | Round 2 PCR RT gene            |
| RT3      | 2474–2504                     | TCCCCAAATGACTAGTGCTTTTTTCCTAT         | Round 1 PCR PR gene            |
| PR1      | 3109–3088                     | GGATGATATCTTAATAGCTAG                 | Sequencing RT gene             |
| PR3      | 2632–2652                     | GGATGATATCTTAATAGCTAG                 | Sequencing PR gene             |
| DP27     | 2360–2380                     | TAGATTTAATGACATGCCTAA                 | Sequencing RT gene             |
| RT3      | 2474–2504                     | GAGGCTATTAAAGAGATCTGCAAAATAGTGG        | Round 2 PCR RT gene            |
| RT5-HIV2 | 3586–3506                     | TCCCCAAATGACTAGTGCTTTTTTCCTAT         | Sequencing RT gene             |
| RT4      | 3500–3529                     | GATGATATCTTAATAGCTAG                 | Sequencing PR gene             |
| RT6-HIV2 | 3505–3689                     | GGATGATATCTTAATAGCTAG                 | Sequencing PR gene             |
| PR2      | 3109–3088                     | GGATGATATCTTAATAGCTAG                 | Sequencing RT gene             |
| PR3      | 2632–2652                     | GGATGATATCTTAATAGCTAG                 | Sequencing PR gene             |

Adapted from Rodes et al.[35] HIV-2 = human immunodeficiency virus type 2, PCR = polymerase chain reaction, PR = protease, RT = reverse transcriptase.

3. Results

3.1. Demographic and clinical characteristics

Sixteen HIV-2 and HIV-1/2 dual-infected patients from 2 hospitals in Southern Ghana were enrolled into the study from December 2014 to May 2015. Eleven of these patients were HIV-2 infected and 5 were HIV-1/2 dual infected. Ten were ART-naive and 6 were ART-experienced. Demographic, clinical and viral load data of study patients are shown in Table 2. Four of the ART-experienced patients were infected with HIV-2 and the remaining 2 were infected with HIV-1/2. Treatment options differed in the 2 ART care centers for both HIV-2 and HIV-1/2 patients. The details of the composition of individual regimen are shown in Figure 1.

3.2. HIV-2 viral load and CD4 cell counts

HIV-2 RNA was detected in the plasma of 9 out of the 16 study patients; 7 were ART-naive and 2 were on treatment. Three had detectable RNA below the LLOQ and 6 had quantifiable viral loads ranging from 2.62 to 5.45 log IU/ml (Table 2). The highest viral load (5.45 log IU/ml) was recorded in an ART-naïve patient; the highest viral load in an ART-experienced patient was 4.62 log IU/ml.

Generally, cluster of differentiation 4 (CD4) cell counts ranged from 11 to 916 cells/μl. The least (11 cells/μl) and highest (916 cells/μl) CD4 cell count were recorded in the ART-naive group (Table 2). Patients CD4 cell count taken at baseline and enrollment are shown in Figure 1.
3.3. PCR and sequencing of the RT and PR genes from plasma and PBMC

The RT and PR genes were successfully amplified in 5 and 4 samples, respectively. For the RT gene, 4 of the samples amplified were from PBMC and 1 was from plasma. All 5 of these samples were successfully sequenced. Included in this group were sequences obtained from both plasma and PBMC of 1 HIV-2 ART-naïve patient. For the PR gene, 2 were amplified from PBMC and the other 2 from plasma, all from ART-naïve patients. Sequences were only obtained from the PBMC amplicon (Table 3).

3.4. HIV-2 grouping and drug resistance mutation analysis

Five sequences from the RT region were identified as HIV-2 group B, including those obtained from the paired plasma and PBMC portions of the blood. Two PR sequences were both HIV-2 group A. One patient (KBAN-14-01) had RT and PR sequences that were classified in different groups; RT as group B and PR as group A (Table 3).

There were no drug resistance-conferring mutations in any of the sequences derived from ART-naïve patients. In the ART-experienced patient, 3 major drug resistance mutations (M184V, K65R, and Y115F) were found in both the PBMC and plasma sequences. These mutations were classified as NNRTI resistant (Table 3).
4. Discussion

Attempts to curb the HIV menace globally are almost exclusively focused on HIV-1. The need for HIV-2 viral load and genotyping protocols to monitor HIV-2 infected patients in regions where HIV-1 and HIV-2 cocirculate is imperative. In this study, we estimated HIV-2 viral loads and detected drug resistance mutations by sequencing the RT and PR genes in HIV-2 strains from HIV-2 and HIV-1/2 dual-infected patients in Ghana.

HIV-2 strains in our study were found to belong to groups A and B, with group B predominating thus supporting previous reports on the HIV-2 epidemic.[44,45] In addition, we also identified 1 intergroup (A/B) recombinant HIV-2 strain. This strain was classified as group A in the PR gene and group B in the RT gene. Similar recombinant HIV-2 strains had been documented previously in Cote d’Ivoire and Cameroon.[43,44] Our study identified matching HIV-2 drug resistance mutations in plasma and PBMC from the same patient. A previous study also documented matching drug resistance mutations in paired PBMC and plasma for HIV-1.[45] This finding from our study supports the recommendations for the use of PBMC as an alternative to plasma for resistance testing, particularly in patients with low plasma viral loads.[46]

Major drug resistance mutations M184V, K65R, and Y115F were detected in an ART-experienced patient. These key mutations had been reported in genotyping analysis elsewhere.[3,47-49] The K65R and Q151M substitutions are known to occur more commonly in HIV-2 than in HIV-1 infections,[40,41] and often appear together with M184V in patients that receive NRTI, as shown in an ART-experienced patient in this study. The presence of K65R is indicative of class-wide nucleoside analogue resistance. The occurrence of Y115F, abacavir-induced mutation, together with M184V, which reduces the susceptibility of lamivudine (3TC), emtricitabine, and abacavir confers possible resistance to the drugs in the NRTIs class. This ART-experienced patient was on a regimen containing 2 NRTIs (lamivudine; tenofovir [TDF]) and 1 NNRTI (nevirapine). Such a patient did probably not derive much therapeutic benefit, because HIV-2 strains are known to be naturally resistant to NNRTIs.[50,51] This patient thus received dual therapy of 3TC and TDF and was thus more prone to accumulate NRTI resistance mutations that will eventually lead to treatment failure. The T cell CD4 count for this patient (76 cells/ul) indicated immunological failure but this information was not available to the clinician at the time of sampling due to nationwide shortage of CD4 reagents; the information only became available because of our study.

Ideally, patients with CD4 cell count less than 350 cells/μl should initiate therapy as per the ART guidelines in Ghana but this was observed due to an acute shortage of CD4 reagents. Based on the Ghana National ART guidelines, this HIV-2 patient should not have been on an NNRTI-based regimen.

However, the clinician managed the patient with respect to HIV-1 infection; the predominant virus. This patient had the highest HIV-2 viral load (4.62 IU/ml) among ART-experienced patients and thus a high possibility of transmitting drug-resistant HIV-2. Availability of HIV typing or HIV-2 viral load data at the time of enrollment for this patient would have probably informed a more suitable regimen and curtailed the emergence of resistance mutations. A high viral load (5.45 IU/ml) was also detected in an ART-naive patient indicating potential high risk of HIV-2 transmission. The lack of an HIV-2 viral load assay to monitor the progress of patients on therapy at the time of sampling is a limitation to this study. Generally, the lack of commercially available assay for HIV-2 viral load is a major limitation in monitoring HIV-2 infected patients on therapy.

Our study did not find any drug resistance mutations in ART-naive patients, implying the absence of transmitted drug resistance. This finding is in contrast to observations in previous studies in Burkina Faso, Guinea Bissau, Belgium, andLuxembourg, where transmitted drug-resistant HIV-2 strains were reported in ART-naive patients.[29,51,52]

The presence of NRTI mutations M184V, K65R, and Y115F found in an ART-experienced person in this study confirms the emergence of ART resistance to the currently available antiretroviral drugs under drug pressure.

This is the first report on HIV-2 viral load and drug resistance mutations in patients infected with either HIV-2 or HIV-1/2 in Ghana. The study showed evidence of major mutations in HIV-2 strains of patients receiving HIV-1 targeted ART. This underscores the need for continuous monitoring of HIV-2 resistance mutations to improve clinical management of HIV-2 patients.

Author contributions

Conceptualization: Christopher Z. Abana, Evelyn Y. Bonney, James A. M. Brandful, William K. Ampofo.
Funding acquisition: Christopher Z. Abana, William K. Ampofo.
Investigation: Christopher Z. Abana.

Supplementary Table

HIV-2 groups and drug resistance mutations from the ART-naive and experienced patients.

| Sample ID    | Treatment history | Gene sequenced | Mutations | Drug resistance | HIV-2 group and % similarity to closest reference isolate |
|--------------|-------------------|----------------|-----------|-----------------|----------------------------------------------------------|
| KFAN-15-01   | None              | RT             | None      | None            | B (88)                                                   |
| KFAN-15-13   | None              | PR             | None      | None            | B (86)                                                   |
| KBAN-14-01   | None              | PR             | None      | None            | B (83)                                                   |
| KFAN-15-04   | 3TC, TDF, NVP     | RTb            | M184V, K65R, Y115F | 3TC, TDF, ABC, AZT, D4T, DDI, FTC | B (92)                                                   |
| KBAN-14-01   | 3TC, TDF, NVP     | RTm            | M184V, K65R, Y115F | 3TC, TDF, ABC, AZT, D4T, DDI, FTC | B (91)                                                   |

Analysis of sequences from ART-naive and ART-experienced patients using HIV-2 EUv2 online tool. The sequences from the RT and PR genes from the ART-naive and experienced patients are susceptible to the class of NRTI and PI drugs. Two sequences were generated from the PR and RT gene of 1 patient (KBAN-14-01). These sequences were HIV-2 group A from the PR gene and HIV-2 Group B from the RT gene. In the ART-experienced patient (KFAE-15-01), the sequence analysis illustrates the mutations conferring NRTI resistance from the PBMC (b) and plasma (m), respectively. The HIV-2 group and percentage similarity to closest reference isolate have been presented. Mutations are denoted by the wild type amino acid followed by the position on the gene and the mutant amino acid.

3TC = lamivudine, AZT = zidovudine, D4T = stavudine, DDI = didanosine, FTC = emtricitabine, HIV-2 = human immunodeficiency virus type 2, NNRTI = EFV = efavirenz, NRTI = ABC = abacavir, NVP = nevirapine, TDC = tenofovir, PR = protease, RT = reverse transcriptase.
Methodology: Christopher Z. Abana, Evelyn Y. Bonney, Ishmael D. Aziai, Esinam Agbosu, Gifty Mawuli, Linda M. Styer, James A. M. Brandful, William K. Ampofo.

Resources: Koichi Ishikawa, James A. M. Brandful, William K. Ampofo.

Software: Evelyn Y. Bonney, Ishmael D. Aziai, Esinam Agbosu.

Supervision: Kwamena W. C. Sagoe, Evelyn Y. Bonney, Linda M. Styer, James A. M. Brandful, William K. Ampofo.

Writing – original draft: Christopher Z. Abana.

Writing – review and editing: Kwamena W. C. Sagoe, Evelyn Y. Bonney, Edward K. Maina, Ishmael D. Aziai, Esinam Agbosu, Gifty Mawuli, Linda M. Styer, James A. M. Brandful, William K. Ampofo.

References

[1] Joint United Nations Programme on HIV/AIDS (UNAIDS). “Global HIV statistics.” Fact sheet July (2017).

[2] Barré-Sinoussi F, Cerny JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (80-) 1983;220:868–71.

[3] Campbell-Yeatts OT, Gandhi RT. Update on human immunodeficiency virus (HIV-2) infection. Clin Infect Dis 2011;52:780–7.

[4] Gottlieb GS, Fischl MA, Hammer SM, et al. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: recommendations of the US Department of Health and Human Services and the HIV Medicine Association of the American Academy of HIV Medicine in collaboration with other organizations. Clin Infect Dis 2011;53:e1–46.

[5] Menéndez-Arias L, Álvarez M. Antiretroviral therapy and drug resistance in patients infected with human immunodeficiency virus type 2. Antiviral Res 2020;106:104827.

[6] Nsagha DS, Njunda AL, Kamga HLF, et al. HIV-1/HIV-2 co-infection and treatment-related factors: analysis of 227 cases from Kinshasa, Democratic Republic of the Congo. J Acquir Immune Defic Syndr 2015;69:12–18.

[7] Rodés B, Holguín A, Soriano V, et al. Emergence of drug resistance mutations in treatment-experienced and treatment-naive patients in the gambia and implications for antiretroviral therapy. J Acquir Immune Defic Syndr 2015;69:94–9.

[8] Styer LM, Miller TT, Parker JM. Validation and clinical use of a sensitive HIV-2 viral load assay that uses a whole virus internal control. J Clin Virol 2003;26:129–31.

[9] Sullivan KM, Dean A, Minn MS. OpenEpi: a web-based epidemiologic and statistical calculator for public health. Public Health Rep 2009;124:471–4.

[10] Van Rompot E, de Mendoza C, Caballero E, et al. Drug resistance mutations in patients infected with HIV-1 in France. J Antimicrob Chemother 2013;68:2051–3.

[11] Wainberg MA. HIV-1 subtype distribution and the problem of drug resistance. AIDS 2004;18:S63–9.

[12] Wainberg MA, Hadler S, Robertson DL, et al. Genetic diversity of human immunodeficiency virus type 2: implications for drug therapy and treatment-related factors. J Virol 1999;73:3796–803.

[13] Wainberg MA, Hadler S, Robertson DL, et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol 1999;63:7433–47.

[14] Yamaguchi J, Vallari A, Ndembi N, et al. HIV-1 subtype C recombinant identified in Cameroon. AIDS 2004;18:4677–81.
[46] Chew CB, Potter SJ, Wang B, et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol 2005;33:206–16.

[47] Damond F, Worobey M, Campa P, et al. Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. AIDS Res Hum Retroviruses 2004;20:666–72.

[48] Descamps D, Damond F, Matheron S, et al. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004;74:197–201.

[49] van der Ende ME, Prins JM, Brinkman K, et al. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 2003;17:555–61.

[50] Ntemgwa ML, Toni Td, Brenner BG, et al. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother 2009;53:3611–9.

[51] Peterson K, Jallow S, Rowland-Jones SL, et al. Antiretroviral therapy for HIV-2 infection: recommendations for management in low-resource settings. AIDS Res Treat 2011;2011.

[52] Witvrouw M, Pannecoque C, Van Laethem K, et al. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 1999;13:1477–83.